Drug Search Results
More Filters [+]

REGN-5837

Alternative Names: REGN-5837, REGN 5837, REGN5837
Latest Update: 2023-05-01
Latest Update Note: Clinical Trial Update

Product Description

REGN5837, a bispecific antibody that clusters CD22-expressing tumor cells with CD28-expressing T cells, enhances odronextamab by potentiating T cell activation and cytolytic function. REGN5837 monotherapy shows limited activity and no toxicity in primate studies, it augments T cell activation when dosed in combination with odronextamab. (Sourced from: https://investor.regeneron.com/static-files/3f2c8835-1da3-43e6-a50d-7080d8d935ab)

Mechanisms of Action: CD22 Inhibitor,CD28 Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for REGN-5837

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ATHENA-1

P1

Recruiting

Lymphoma, Non-Hodgkin|Lymphoma, B-Cell

2027-06-02

50%

Recent News Events

Date

Type

Title